XBI

Bull’s Eye Report: Regeneron Pharmaceuticals (REGN)

REGN gained 208.65% on the year in 2012, and while normally this would indicate a parabolic run, the short-term prospects for a trade still look pretty good. More 

My Brilliant Biotech Move for 2012

An overly helter-skelter year in the world of biotech stocks has been a stark reminder of a basic lesson that isn't followed enough: Keep it simple. More 

Are You Missing the Biotech Boat?

Biotech stocks have been one of the market's best performing areas during the past year and beyond. Is it too late to catch this comet? More 

The Best Ways to Play Sectors Right Now

A shrinking correlation among stocks means harder decisions. Here's some sectors you should play with a fund, and others where you should go stock-picking. More